Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may have a surface compressive stress of at least 350 MPa.

Abstract: Disclosed herein are glasses that present several advantages over traditional glass compositions used in optical applications. The glasses disclosed herein have a low devitrification tendency and can be processed by melt quenching and formed into macroscopic components. The glasses have high glass thermal stability indices and are chemically durable. The glasses disclosed herein are transparent when heat treated in air or oxygen and have high refractive indices and low density, as well, making them suitable for optical applications.

Abstract: The present disclosure provides a blade inspection device, a method and a printing modification device, and belongs to the technical field of screen printing. The blade inspection device includes a telescopic component, a driving component and a parameter obtaining module. The driving component is configured to drive the telescopic component to move in a direction parallel to the line where the blade is located. The parameter obtaining module is configured to obtain a first parameter to inspect the blade according to the first parameter. The first parameter is related to a displacement of the first end of the telescopic component in a direction perpendicular to the line where the blade is located.

Abstract: A borophosphate glass composition including B2O3, P2O5, and CaO, and optionally a source additive selected from: Li2O, Na2O, K2O, Al2O3, ZnO, MgO, Fe2O3/FeO, CuO/Cu2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B2O3, P2O5, and CaO.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B2O3, SrO, BaO, and ZrO2.

Abstract: An optical boroaluminate glass article comprises: from greater than or equal to 10.0 mol % to less than or equal to 30.0 mol % Al2O3; from greater than or equal to 10.0 mol % to less than or equal to 55.0 mol % CaO; from greater than or equal to 10.0 mol % to less than or equal to 25.0 mol % B2O3; from greater than or equal to 0.0 mol % to less than or equal to 30.0 mol % SiO2; and from greater than or equal to 1.0 mol % to less than or equal to 20.0 mol % refractive index raising components. The optical boroaluminate glass article has a refractive index of the glass article, measured at 589.3 nm, of greater than or equal to 1.62, and a density of less than or equal to 4.00 g/cm3.

Abstract: A borate glass includes from 25.0 mol % to 70.0 mol % B2O3; from 0.0 mol % to 10.0 mol % SiO2; from 0.0 mol % to 15.0 mol % Al2O3; from 3.0 mol % to 15.0 mol % Nb2O5; from 0.0 mol % to 12.0 mol % alkali metal oxides; from 0.0 mol % to 5.0 mol % ZnO; from 0.0 mol % to 8.0 mol % ZrO2; from 0.0 mol % to 15.0 mol % TiO2; less than 0.5 mol % Bi2O3; and less than 0.5 mol % P2O5. The optical borate glass includes a sum of B2O3+Al2O3+SiO2 from 35.0 mol % to 76.0 mol %, a sum of CaO+MgO from 0.0 mol % to 35.5 mol %. The borate glass has a refractive index, measured at 587.6 nm, of greater than 1.70, a density of less than 4.50 g/cm3, and an Abbe number, VD, from 20.0 to 47.0.

Abstract: A glass pharmaceutical package having a glass composition of 68.00 mol % to 81.00 mol % SiO2, from 4.00 mol % to 11.00 mol % Al2O3, from 0.10 mol % to 16.00 mol % Li2O, from 0.10 mol % to 12.00 mol % Na2O, from 0.00 mol % to 5.00 mol % K2O, from 0.10 mol % to 8.00 mol % MgO, from 0.10 mol % to 5.00 mol % CaO, from 0.00 mol % to 0.20 mol % fining agent. The glass pharmaceutical package is delamination resistant, and has class 1 or class 2 chemical durability in acid, base, and water. The glass pharmaceutical package may be substantially free of B2O3, SrO, BaO, and ZrO2.

Abstract: A borophosphate glass composition including B2O3, P2O5, and CaO, and optionally a source additive selected from: Li2O, Na2O, K2O, Al2O3, ZnO, MgO, Fe2O3/FeO, CuO/Cu2O, and mixtures thereof, as defined herein. Also disclosed are bioactive compositions or substrates including the disclosed borophosphate glass composition, and at least one live cell. Also disclosed are methods of inhibiting or increasing the relative amount of species containing boron, phosphorous, or both, being released into an aqueous solution from aborophosphate glass composition defined herein. Also disclosed is a method of proliferating cells on a bioactive substrate as defined herein. Also disclosed are related glass compositions that exclude one of B2O3, P2O5, and CaO.

Abstract: An aluminoborate composition, an alumino-borosilicate glass composition, or a mixture thereof, and solid or hollow microspheres thereof, as defined herein. Also disclosed are methods of making and using the disclosed compositions, for example, forming microspheres for use in bioactive applications, and composition extracts for use in treating or healing wounds.